Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. [electronic resource]
Producer: 20030121Description: 3686-95 p. digitalISSN:- 1078-0432
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antigens, CD -- metabolism
- Apoptosis -- drug effects
- Cytokines -- metabolism
- Dose-Response Relationship, Drug
- Endothelial Growth Factors -- metabolism
- Female
- Fibroblast Growth Factor 2 -- metabolism
- Gastrointestinal Neoplasms -- drug therapy
- Humans
- Injections, Intraperitoneal
- Intercellular Signaling Peptides and Proteins -- metabolism
- Interferon-gamma -- metabolism
- Interleukin-12 -- adverse effects
- Lymphokines -- metabolism
- Male
- Mesothelioma -- drug therapy
- Middle Aged
- Mullerian Ducts -- pathology
- Ovarian Neoplasms -- drug therapy
- Peritoneal Neoplasms -- drug therapy
- Ploidies
- Recombinant Proteins -- adverse effects
- Tissue Distribution
- Transaminases -- metabolism
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.